Immediate Impact
50 standout
Citing Papers
PI3K/Akt/mTOR Signaling Pathway as a Target for Colorectal Cancer Treatment
2024 Standout
Datopotamab Deruxtecan in Advanced or Metastatic HR+/HER2– and Triple-Negative Breast Cancer: Results From the Phase I TROPION-PanTumor01 Study
2024 Standout
Works of Jodi Lynch being referenced
CDK4/6 inhibitor plus endocrine therapy for hormone receptor‐positive, HER2‐negative metastatic breast cancer: The new standard of care
2021
Phase II, double-blind, randomized trial of capecitabine plus enzastaurin versus capecitabine plus placebo in patients with metastatic or recurrent breast cancer after prior anthracycline and taxane therapy
2010
Author Peers
| Author | Last Decade | Papers | Cites | |||||
|---|---|---|---|---|---|---|---|---|
| Jodi Lynch | 183 | 75 | 94 | 111 | 95 | 26 | 468 | |
| Travis Osterman | 117 | 36 | 55 | 102 | 59 | 31 | 463 | |
| Toufic Eid | 261 | 79 | 81 | 62 | 129 | 20 | 489 | |
| Thomas Budd | 170 | 49 | 103 | 41 | 107 | 21 | 569 | |
| Fariborz Mokarian | 169 | 48 | 46 | 37 | 94 | 42 | 496 | |
| Carmel Malone | 194 | 55 | 73 | 36 | 170 | 21 | 503 | |
| Nasrin Fouladi | 180 | 102 | 97 | 41 | 37 | 18 | 423 | |
| Noorie Hyun | 225 | 17 | 78 | 51 | 62 | 29 | 571 | |
| Tallal Younis | 326 | 92 | 115 | 78 | 163 | 34 | 565 | |
| Gilberto Uemura | 206 | 36 | 35 | 48 | 93 | 26 | 423 | |
| Annelies H. Boekhout | 297 | 62 | 85 | 58 | 28 | 30 | 474 |
All Works
Login with ORCID to disown or claim papers
Loading papers...